Showing Results for: “diabetes”

Findings highlight use of once-weekly injection to expand potential options for weight reduction, A1C control, knee osteoarthritis, and obstructive sleep apnea First-ever type 2 diabetes and obesity phase 3 study results for retatrutide, a novel glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide 1(GLP-1), and glucagon triple hormone receptor agonist, were announced today. The findings demonstrated positive outcomes in people living with obesity and type 2 diabetes, as well as improvements in major complications, including obstructive sleep apnea and knee osteoarthritis

The Centers for Medicare and Medicaid Services (CMS) will continue to prohibit coverage of weight management medications for Medicare and Medicaid enrollees. In response to the announcement, the American Diabetes Association® (ADA) issues the following statement: “The ADA is disappointed the CMS final Contract Year 2026 Medicare Advantage and Part D rule did not address the prohibition of coverage for obesity medications. Obesity is a growing health crisis in the United States that affects over 34% of Medicare beneficiaries and 38% of Medicaid and CHIP enrollees. Obesity is linked to more than

The diabetes medications glimepiride and linagliptin had similar impacts on cardiovascular morbidity and mortality for a median period of 6.3 years, when added to standard care for people with relatively early type 2 diabetes (T2D), many of whom had an elevated risk of cardiovascular disease (CVD) or existing CVD at the beginning of the study, according to research presented today at the American Diabetes Association’s® (ADA’s) 79th Scientific Sessions® at the Moscone Convention Center in San Francisco. The study was featured today at “The CAROLINA Trial—First Results of the Cardiovascular

The American Diabetes Association® (ADA) will present the 2019 Outstanding Scientific Achievement Award (OSAA) to Sadaf Farooqi, MB, ChB (Hons), PhD. Dr. Farooqi will be recognized with this honor, which is given annually for research in diabetes that demonstrates particular independence of thought and originality, during the ADA’s 79th Scientific Sessions, June 7-11, 2019, at the Moscone Convention Center in San Francisco. She will deliver her OSAA Lecture, titled “ Obesity and the Biology of Weight Regulation,” during the National Scientific and Health Care Achievement Awards Presentation on

A step forward, but more progress needs to be made The American Diabetes Association ® (ADA) applauds Monday’s announcement that, effective October 7, 2025, Ohio will launch a new weight management program for state employees. The program will include partial reimbursement for Food and Drug Administration (FDA)-approved GLP-1 medications for state employees who meet medical eligibility criteria. The program, limited to the first 2,500 qualified employees who enroll, includes unlimited support from an expert health coach, nutrition resources, a digital body weight scale, and limited access to

Rallying the community in the fight to end diabetes On April 25, the American Diabetes Association ® (ADA) will host its signature fundraising event, Step Out ® Walk: North Texas, bringing together the diabetes community, volunteers, and Diabetes Advocates to raise awareness and critical funds for people living with diabetes. This year’s walk will feature former Dallas Cowboy and Super Bowl XXV Champion Everson Walls as the grand marshal. Since 2025, Walls has served as an all-star ambassador for the ADA and a strong voice in the fight to end diabetes and find a cure. Time: 9:00 a.m. Location

Today, the American Diabetes Association ® (ADA) released its much-anticipated annual Standards of Medical Care in Diabetes (Standards of Care). Based upon the latest scientific diabetes research and clinical trials, Standards of Care is the gold-standard for professionals in the medical field and includes vital new and updated practice guidelines to care for people with diabetes and prediabetes. "We recognize that health care providers around the world look to our Standards of Care for the latest in how new research can impact care and are excited to provide this valuable resource," said Dr

Today, the American Diabetes Association® released the 2021 Standards of Medical Care in Diabetes. The 2021 Standards of Care is now live online in Diabetes Care. Based upon the latest scientific diabetes research and clinical trials, the Standards of Care includes new and updated recommendations and guidelines to care for people with diabetes. The Standards of Medical Care in Diabetes—2021 provides the latest in comprehensive, evidence-based recommendations for the diagnosis and treatment of children and adults with type 1, type 2, or gestational diabetes; strategies for the prevention or

The American Diabetes Association ® (ADA) is thrilled to present the fourth annual Kiss a Pig Gala in New Orleans on July 26. This black-tie event honors the role pigs played in diabetes treatment. All proceeds from the gala support the ADA’s mission to prevent and cure diabetes and to improve the lives of all people affected by diabetes. Each year, industry leaders unite to celebrate the candidates who have been raising funds throughout the year for diabetes research. Ten candidates are selected to participate in the event. Each candidate runs a peer-to-peer fundraising campaign, and the top

Results Demonstrate Enhanced Diabetes Management and Quality of Life with Advanced Technology New data focused on advanced technology innovations for managing type 2 diabetes (T2D) highlight the positive impact of automated insulin delivery systems (AID) and continuous glucose monitoring (CGM) in improving glycemic control and overall diabetes management. Three studies showing advancements for type 2 diabetes were presented at the American Diabetes Association’s ® (ADA) 84th Scientific Sessions in Orlando, FL. Of the nearly 40 million Americans with diabetes, more than 90% have type 2 diabetes